COPENHAGEN, Denmark — September 22, 2026
Zealand Pharma announced the initiation of the global registrational Phase 3a ZUPREME program evaluating once-weekly petrelintide for chronic weight management in people with overweight or obesity. Developed in collaboration with Roche, the program comprises three randomized, double-blind, placebo-controlled trials designed to evaluate petrelintide monotherapy across populations with obesity or overweight, with and without type 2 diabetes, and in people with established cardiovascular disease. The program is expected to enroll approximately 7,000 participants and is intended to support future regulatory applications for petrelintide.
ZUPREME Program Covers Three Patient Populations
The ZUPREME-3, ZUPREME-4 and ZUPREME-5 trials are designed to evaluate petrelintide across distinct populations with high unmet needs in chronic weight management. ZUPREME-3 will enroll approximately 3,900 participants with overweight or obesity and at least one weight-related comorbidity but without type 2 diabetes. ZUPREME-4 will evaluate approximately 600 participants with overweight or obesity and type 2 diabetes, while ZUPREME-5 will enroll approximately 2,500 participants with overweight or obesity and established cardiovascular disease, with or without type 2 diabetes. The primary efficacy endpoint across the program is percentage change in body weight from baseline to Week 64.
Petrelintide Advances on Positive Phase 2 Results
The Phase 3 program builds on Phase 2 results that demonstrated double-digit weight loss with a tolerability profile reported as largely comparable to placebo, according to Zealand Pharma. Petrelintide is a long-acting amylin analog designed for once-weekly subcutaneous administration. Activation of the amylin receptor is associated with increased satiety and effects on body weight. The ZUPREME-3 and ZUPREME-4 studies include a 12-week dose-escalation period followed by maintenance treatment through Week 64, with eligible participants able to enter an optional open-label extension. ZUPREME-5 includes an event-maintenance phase and may continue for up to three years.
Zealand and Roche Expand Petrelintide Development
The ZUPREME program represents a major expansion of the Zealand Pharma-Roche collaboration in metabolic health, with petrelintide being developed both as a monotherapy and in combination with Roche’s GLP-1/GIP receptor dual agonist enicepatide (CT-388). A Phase 2 study of the petrelintide and enicepatide combination is planned for the second half of 2026. In addition to weight change, the Phase 3 program will assess measures including waist circumference, HbA1c, cardiometabolic risk factors, physical functioning and eating behaviors, generating a broader dataset to support the potential regulatory development of petrelintide in chronic weight management.
Source :Zealand Pharma press release



